Adma Biologics (ADMA) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $10.73, +3.77% vs the prior close of $10.34.
- Volume 2.77M shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ADMA jumps 3.8% to $10.73, a 3-month high, 3 up days in a row. Closed at $10.73, +3.77% vs the prior close of $10.34. Day range $10.48–$10.91, opened at $10.60.
ADMA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — ADMA jumps 3.8% to $10.73, a 3-month high, 3 up days in a row
- Closed at $10.73, +3.77% vs the prior close of $10.34. Day range $10.48–$10.91, opened at $10.60.
- Volume was 2.77M shares, 1.0x its 50-day average of 2.72M.
- Price is +10.7% vs its 50-day average ($9.69) and -5.4% vs its 200-day average ($11.34).
- 52-week range $7.21–$20.46; today's close sits at 27% of that range, 47.6% below the 52-week high.
- That makes 3 straight gains.
Oct 14, 2026 — ADMA ends flat (+0.3%) to $10.34
- Closed at $10.34, +0.29% vs the prior close of $10.31. Day range $10.23–$10.60, opened at $10.31.
- Volume was 2.88M shares, 1.1x its 50-day average of 2.72M.
- Price is +7.0% vs its 50-day average ($9.66) and -9.2% vs its 200-day average ($11.39).
- 52-week range $7.21–$20.46; today's close sits at 24% of that range, 49.5% below the 52-week high.
Oct 13, 2026 — ADMA rises 1.3% to $10.31
- Closed at $10.31, +1.28% vs the prior close of $10.18. Day range $10.02–$10.35, opened at $10.19.
- Volume was 3.77M shares, 1.4x its 50-day average of 2.70M.
- Price is +7.0% vs its 50-day average ($9.63) and -9.8% vs its 200-day average ($11.43).
- 52-week range $7.21–$20.46; today's close sits at 23% of that range, 49.6% below the 52-week high.
Oct 12, 2026 — ADMA dips 1.7% to $10.18
- Closed at $10.18, -1.74% vs the prior close of $10.36. Day range $10.16–$10.40, opened at $10.32.
- Volume was 1.63M shares, 0.6x its 50-day average of 2.70M.
- Price is +6.0% vs its 50-day average ($9.60) and -11.3% vs its 200-day average ($11.48).
- 52-week range $7.21–$20.46; today's close sits at 22% of that range, 50.2% below the 52-week high.
Oct 9, 2026 — ADMA ends flat (+0.3%) to $10.36, a 3-month high
- Closed at $10.36, +0.29% vs the prior close of $10.33. Day range $10.25–$10.51, opened at $10.32.
- Volume was 2.83M shares, 1.1x its 50-day average of 2.66M.
- Price is +8.3% vs its 50-day average ($9.57) and -10.1% vs its 200-day average ($11.52).
- 52-week range $7.21–$20.46; today's close sits at 24% of that range, 49.4% below the 52-week high.
Oct 8, 2026 — ADMA rises 1.9% to $10.33, a 3-month high
- Closed at $10.33, +1.87% vs the prior close of $10.14. Day range $10.03–$10.44, opened at $10.09.
- Volume was 3.90M shares, 1.5x its 50-day average of 2.63M.
- Price is +8.3% vs its 50-day average ($9.54) and -10.7% vs its 200-day average ($11.57).
- 52-week range $7.21–$20.46; today's close sits at 24% of that range, 49.5% below the 52-week high.
Oct 7, 2026 — ADMA dips 0.4% to $10.14
- Closed at $10.14, -0.39% vs the prior close of $10.18. Day range $10.07–$10.32, opened at $10.15.
- Volume was 3.05M shares, 1.2x its 50-day average of 2.61M.
- Price is +6.7% vs its 50-day average ($9.50) and -12.7% vs its 200-day average ($11.62).
- 52-week range $7.21–$20.46; today's close sits at 22% of that range, 50.4% below the 52-week high.
Oct 6, 2026 — ADMA rises 0.7% to $10.18, a 3-month high
- Closed at $10.18, +0.69% vs the prior close of $10.11. Day range $9.98–$10.35, opened at $10.20.
- Volume was 2.10M shares, 0.8x its 50-day average of 2.62M.
- Price is +7.4% vs its 50-day average ($9.48) and -12.7% vs its 200-day average ($11.66).
- 52-week range $7.21–$20.46; today's close sits at 22% of that range, 50.2% below the 52-week high.
Oct 5, 2026 — ADMA jumps 4.0% to $10.11
- Closed at $10.11, +4.01% vs the prior close of $9.72. Day range $9.62–$10.19, opened at $9.63.
- Volume was 3.51M shares, 1.4x its 50-day average of 2.59M.
- Price is +7.1% vs its 50-day average ($9.44) and -13.6% vs its 200-day average ($11.70).
- 52-week range $7.21–$20.46; today's close sits at 22% of that range, 50.6% below the 52-week high.
Oct 2, 2026 — ADMA dips 2.1% to $9.72
- Closed at $9.72, -2.11% vs the prior close of $9.93. Day range $9.68–$10.28, opened at $10.02.
- Volume was 2.79M shares, 1.1x its 50-day average of 2.59M.
- Price is +3.4% vs its 50-day average ($9.40) and -17.3% vs its 200-day average ($11.75).
- 52-week range $7.21–$20.46; today's close sits at 19% of that range, 52.5% below the 52-week high.
ADMA latest news & SEC filings
Every SEC filing by or about ADMA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $124.39M (prior year $121.98M) (+2.0% vs Jun 30, 2025)
- Net income: $37.82M (prior year $34.22M) (+10.5% vs Jun 30, 2025)
- Diluted EPS: $0.16 (prior year $0.14) (+14.3% vs Jun 30, 2025)
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 28, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Things to know before you trade ADMA
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 6, 2026, Feb 25, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.07% (largest 7.9%).
- Liquidity: about 3.43M shares (≈$36.84M) trade per day on average.
- 52-week position: $10.73 vs a range of $7.21–$20.46 (27% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 5 open-market buys, 11 sales; latest: Jerrold B Grossman bought 6,400 shares on May 27, 2026.
- Latest filings: 10-Q Aug 5, 2026; 8-K Aug 5, 2026; 8-K Jun 2, 2026.
- Share count: 223.98M shares outstanding (Jul 31, 2026), -6.1% vs a year earlier — the company has been reducing its share count.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
ADMA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 10.60 | 10.91 | 10.48 | 10.73 | 2.77M |
| Oct 14, 2026 | 10.31 | 10.60 | 10.23 | 10.34 | 2.88M |
| Oct 13, 2026 | 10.19 | 10.35 | 10.02 | 10.31 | 3.77M |
| Oct 12, 2026 | 10.32 | 10.40 | 10.16 | 10.18 | 1.63M |
| Oct 9, 2026 | 10.32 | 10.51 | 10.25 | 10.36 | 2.83M |
| Oct 8, 2026 | 10.09 | 10.44 | 10.03 | 10.33 | 3.90M |
| Oct 7, 2026 | 10.15 | 10.32 | 10.07 | 10.14 | 3.05M |
| Oct 6, 2026 | 10.20 | 10.35 | 9.98 | 10.18 | 2.10M |
| Oct 5, 2026 | 9.63 | 10.19 | 9.62 | 10.11 | 3.51M |
| Oct 2, 2026 | 10.02 | 10.28 | 9.68 | 9.72 | 2.79M |
| Oct 1, 2026 | 10.07 | 10.26 | 9.90 | 9.93 | 3.97M |
| Sep 30, 2026 | 9.98 | 10.14 | 9.80 | 10.03 | 2.70M |
| Sep 29, 2026 | 10.03 | 10.19 | 9.89 | 9.96 | 3.46M |
| Sep 28, 2026 | 9.38 | 10.17 | 9.25 | 10.12 | 3.57M |
| Sep 25, 2026 | 9.55 | 9.62 | 9.23 | 9.38 | 3.57M |
| Sep 24, 2026 | 9.67 | 9.82 | 9.37 | 9.52 | 2.59M |
| Sep 23, 2026 | 9.81 | 9.84 | 9.43 | 9.70 | 2.60M |
| Sep 22, 2026 | 9.53 | 9.84 | 9.45 | 9.81 | 2.74M |
| Sep 21, 2026 | 9.19 | 9.54 | 9.10 | 9.51 | 2.86M |
| Sep 18, 2026 | 8.92 | 9.13 | 8.81 | 9.11 | 11.40M |
About Adma Biologics
Adma Biologics (ADMA) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in RAMSEY, NJ. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1368514.
ADMA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Steve Elms | Director | Mar 9, 2026 |
| Alison Cecily Finger | Director | Feb 11, 2026 |
| Adam S Grossman | President and CEO | Mar 17, 2026 |
| Jerrold B Grossman | Director | May 28, 2026 |
| Lawrence P. Guiheen | Director | Mar 17, 2026 |
| Young Kwon | Director | Feb 11, 2026 |
| Eduardo Rene Salas | Director | Feb 11, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Adam S Grossman | President and CEO | Mar 17, 2026 |
| Kaitlin M. Kestenberg-Messina | COO and SVP, Compliance | Jul 28, 2026 |
| Terry Kohler | CFO and Treasurer | Jul 17, 2026 |
| Brad L. Tade | CFO and Treasurer | Feb 23, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 27, 2026 | Jerrold B Grossman | Buy | 6,400 | $7.91 |
| May 12, 2026 | Jerrold B Grossman | Buy | 12,500 | $8.01 |
| May 11, 2026 | Jerrold B Grossman | Buy | 12,500 | $8.01 |
| Mar 16, 2026 | Adam S Grossman | Sale | 6,000 | $15.16 |
| Mar 16, 2026 | Adam S Grossman | Sale | 15,000 | $15.16 |
| Mar 9, 2026 | Kaitlin M. Kestenberg-Messina | Sale | 10,096 | $15.63 |
| Mar 6, 2026 | Steve Elms | Buy | 7,000 | $15.39 |
| Mar 5, 2026 | Steve Elms | Buy | 7,000 | $15.67 |
| Feb 17, 2026 | Adam S Grossman | Sale | 6,000 | $16.08 |
| Feb 17, 2026 | Adam S Grossman | Sale | 15,000 | $16.08 |
| Dec 15, 2025 | Adam S Grossman | Sale | 6,000 | $19.79 |
| Dec 15, 2025 | Adam S Grossman | Sale | 15,000 | $19.79 |
| Nov 19, 2025 | Adam S Grossman | Sale | 6,000 | $16.00 |
| Nov 19, 2025 | Adam S Grossman | Sale | 15,000 | $16.00 |
| Oct 24, 2025 | Adam S Grossman | Sale | 15,000 | $16.00 |
ADMA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $510.17M | $146.93M | 0.60 | $50.40M |
| Dec 31, 2024 | $426.45M | $197.67M | 0.81 | $118.67M |
| Dec 31, 2023 | $258.21M | $-28.24M | -0.13 | $8.80M |
| Dec 31, 2022 | $154.08M | $-65.90M | -0.33 | $-59.51M |
| Dec 31, 2021 | $80.94M | $-71.65M | -0.51 | $-112.37M |
Latest balance sheet: total assets $684.21M, total liabilities $276.00M, cash $136.02M (as of Jun 30, 2026).
ADMA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $9.26 |
| May 6, 2026 | 8-K Item 2.02 (results) | $10.08 |
| Feb 25, 2026 | 8-K Item 2.02 (results) | $15.68 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $17.93 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $15.37 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $18.54 |
| May 7, 2025 | 8-K Item 2.02 (results) | $23.61 |
| Mar 3, 2025 | 8-K Item 2.02 (results) | $15.83 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $16.49 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $19.72 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on ADMA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.